Literature DB >> 22726582

Analysis of outcomes after radical prostatectomy in patients eligible for active surveillance (PRIAS).

Albert El Hajj1, Guillaume Ploussard, Alexandre de la Taille, Yves Allory, Dimitri Vordos, Andras Hoznek, Claude Clément Abbou, Laurent Salomon.   

Abstract

OBJECTIVE: To identify the risk of failure of active surveillance (AS) in men who had the Prostate Cancer Research International: Active Surveillance (PRIAS) criteria and had undergone radical prostatectomy (RP), by studying as primary endpoints the risk of unfavourable disease in RP specimens (stage >T2 and/or Gleason score >6) and of biochemical progression after RP. PATIENTS AND METHODS: We assessed 626 patients who had the PRIAS criteria for AS defined as T1c/T2, PSA level of ≤10 ng/mL, PSA density (PSAD) of <0.2 ng/mL per mL, Gleason score of <7, and one or two positive biopsies. All patients underwent immediate RP at our department between January 1991 and December 2010. Multivariate logistic regression was used to test factors correlated with the risk of unfavourable prostate cancer. The risk of progression was tested using multivariate Cox regression models. Biochemical recurrence-free survival (BFS) was established using the Kaplan-Meier method.
RESULTS: Pathological study of RP specimens showed upstaging (>T2) in 129 patients (20.6%), upgrading (Gleason score >6) in 281 (44.9%) and unfavourable disease in 312 patients (50%). There was a statistically non-significant trend for BFS at P = 0.06. Predictors of favourable tumours were age <65 years (P = 0.005), one vs two positive biopsies (P = 0.01) and a biopsy core number >12 (P = 0.005). Preoperative factors predicting disease progression were a PSAD of >0.15 ng/mL(2) (P = 0.008) and biopsy core number of ≤12 (P = 0.017).
CONCLUSIONS: Even with stringent AS criteria, the rate of unfavourable disease remains high. Predictive factors of unfavourable disease and biochemical progression should be considered when including patients in AS protocols.
© 2012 BJU International.

Entities:  

Mesh:

Year:  2012        PMID: 22726582     DOI: 10.1111/j.1464-410X.2012.11276.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  20 in total

1.  Performance of biopsy factors in predicting unfavorable disease in patients eligible for active surveillance according to the PRIAS criteria.

Authors:  G I Russo; T Castelli; V Favilla; G Reale; D Urzì; S Privitera; E Fragalà; S Cimino; G Morgia
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-06-02       Impact factor: 5.554

2.  Active surveillance in Canadian men with low-grade prostate cancer.

Authors:  Octav Cristea; Luke T Lavallée; Joshua Montroy; Andrew Stokl; Sonya Cnossen; Ranjeeta Mallick; Dean Fergusson; Franco Momoli; Illias Cagiannos; Christopher Morash; Rodney H Breau
Journal:  CMAJ       Date:  2016-02-29       Impact factor: 8.262

3.  Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancer.

Authors:  Matthew Truong; Jon A Slezak; Chee Paul Lin; Viacheslav Iremashvili; Martins Sado; Aria A Razmaria; Glen Leverson; Mark S Soloway; Scott E Eggener; E Jason Abel; Tracy M Downs; David F Jarrard
Journal:  Cancer       Date:  2013-09-04       Impact factor: 6.860

4.  Functional outcomes of robot-assisted radical prostatectomy in patients eligible for active surveillance.

Authors:  Marc Zanaty; Khaled Ajib; Kevin Zorn; Assaad El-Hakim
Journal:  World J Urol       Date:  2018-04-21       Impact factor: 4.226

5.  Oncological and functional outcomes 1 year after radical prostatectomy for very-low-risk prostate cancer: results from the prospective LAPPRO trial.

Authors:  Stefan Carlsson; Fredrik Jäderling; Anna Wallerstedt; Tommy Nyberg; Johan Stranne; Thordis Thorsteinsdottir; Sigrid V Carlsson; Anders Bjartell; Jonas Hugosson; Eva Haglind; Gunnar Steineck
Journal:  BJU Int       Date:  2016-03-18       Impact factor: 5.588

6.  An assessment of Prostate Cancer Research International: Active Surveillance (PRIAS) criteria for active surveillance of clinically low-risk prostate cancer patients.

Authors:  Vitor da Silva; Ilias Cagiannos; Luke T Lavallée; Ranjeeta Mallick; Kelsey Witiuk; Sonya Cnossen; James A Eastham; Dean A Fergusson; Chris Morash; Rodney H Breau
Journal:  Can Urol Assoc J       Date:  2017-08       Impact factor: 1.862

7.  Multiphoton gradient index endoscopy for evaluation of diseased human prostatic tissue ex vivo.

Authors:  David M Huland; Manu Jain; Dimitre G Ouzounov; Brian D Robinson; Diana S Harya; Maria M Shevchuk; Paras Singhal; Chris Xu; Ashutosh K Tewari
Journal:  J Biomed Opt       Date:  2014-11       Impact factor: 3.170

8.  Our results of active surveillance for localized prostate cancer patients.

Authors:  Hasan Soydan; Furkan Dursun; Ömer Yılmaz; Sezgin Okçelik; Ferhat Ateş; Kenan Karademir
Journal:  Turk J Urol       Date:  2013-03

9.  The effect of differing Gleason scores at biopsy on the odds of upgrading and the risk of death from prostate cancer.

Authors:  John G Phillips; Ayal A Aizer; Ming-Hui Chen; Danjie Zhang; Michelle S Hirsch; Jerome P Richie; Clare M Tempany; Stephen Williams; John V Hegde; Marian J Loffredo; Anthony V D'Amico
Journal:  Clin Genitourin Cancer       Date:  2014-03-03       Impact factor: 2.872

10.  Neutrophil and Lymphocyte Counts as Clinical Markers for Stratifying Low-Risk Prostate Cancer.

Authors:  Young Suk Kwon; Christopher Sejong Han; Ji Woong Yu; Sinae Kim; Parth Modi; Rachel Davis; Ji Hae Park; Paul Lee; Yun-Sok Ha; Wun-Jae Kim; Isaac Yi Kim
Journal:  Clin Genitourin Cancer       Date:  2015-08-06       Impact factor: 2.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.